William C Scott1, Katherine N Cahill2, Ginger L Milne2, Ping Li1, Quanhu Sheng3, Li Ching Huang3, Spencer Dennis1, Jacob Snyder1, Ashley M Bauer1, Rakesh K Chandra1, Naweed I Chowdhury1, Justin H Turner4. 1. Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tenn. 2. Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tenn. 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tenn. 4. Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tenn. Electronic address: justin.h.turner@vumc.org.
Abstract
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP). Although frequently associated with type 2 inflammation, literature characterizing the milieu of inflammatory cytokines and lipid mediators in AERD has been conflicting. OBJECTIVE: We sought to identify differences in the upper airway inflammatory signature between CRSwNP and AERD and determine whether endotypic subtypes of AERD may exist. METHODS: Levels of 7 cytokines representative of type 1, type 2, and type 3 inflammation, and 21 lipid mediators were measured in nasal mucus from 109 patients with CRSwNP, 30 patients with AERD, and 64 non-CRS controls. Differences in inflammatory mediators were identified between groups, and patterns of inflammation among patients with AERD were determined by hierarchical cluster analysis. RESULTS: AERD could be distinguished from CRSwNP by profound elevations in IL-5, IL-6, IL-13, and IFN-γ; however, significant heterogeneity existed between patients. Hierarchical cluster analysis identified 3 inflammatory subendotypes of AERD characterized by (1) low inflammatory burden, (2) high type 2 cytokines, and (3) comparatively low type 2 cytokines and high levels of type 1 and type 3 cytokines. Several lipid mediators were associated with asthma and sinonasal disease severity; however, lipid mediators showed less variability than cytokines. CONCLUSIONS: AERD is associated with elevations in type 2 cytokines (IL-5 and IL-13) and the type 1 cytokine, IFN-γ. Among patients with AERD, the inflammatory signature is heterogeneous, supporting subendotypes of the disease. Variability in AERD immune signatures should be further clarified because this may predict clinical response to biologic medications that target type 2 inflammation.
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a mechanistically distinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP). Although frequently associated with type 2 inflammation, literature characterizing the milieu of inflammatory cytokines and lipid mediators in AERD has been conflicting. OBJECTIVE: We sought to identify differences in the upper airway inflammatory signature between CRSwNP and AERD and determine whether endotypic subtypes of AERD may exist. METHODS: Levels of 7 cytokines representative of type 1, type 2, and type 3 inflammation, and 21 lipid mediators were measured in nasal mucus from 109 patients with CRSwNP, 30 patients with AERD, and 64 non-CRS controls. Differences in inflammatory mediators were identified between groups, and patterns of inflammation among patients with AERD were determined by hierarchical cluster analysis. RESULTS: AERD could be distinguished from CRSwNP by profound elevations in IL-5, IL-6, IL-13, and IFN-γ; however, significant heterogeneity existed between patients. Hierarchical cluster analysis identified 3 inflammatory subendotypes of AERD characterized by (1) low inflammatory burden, (2) high type 2 cytokines, and (3) comparatively low type 2 cytokines and high levels of type 1 and type 3 cytokines. Several lipid mediators were associated with asthma and sinonasal disease severity; however, lipid mediators showed less variability than cytokines. CONCLUSIONS: AERD is associated with elevations in type 2 cytokines (IL-5 and IL-13) and the type 1 cytokine, IFN-γ. Among patients with AERD, the inflammatory signature is heterogeneous, supporting subendotypes of the disease. Variability in AERD immune signatures should be further clarified because this may predict clinical response to biologic medications that target type 2 inflammation.
Authors: John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish Journal: J Allergy Clin Immunol Date: 2013-06-24 Impact factor: 10.793
Authors: Bruce K Tan; Rakesh K Chandra; Jonathan Pollak; Atsushi Kato; David B Conley; Anju T Peters; Leslie C Grammer; Pedro C Avila; Robert C Kern; Walter F Stewart; Robert P Schleimer; Brian S Schwartz Journal: J Allergy Clin Immunol Date: 2013-03-28 Impact factor: 10.793
Authors: Michael C Peters; Kelly Wong McGrath; Gregory A Hawkins; Annette T Hastie; Bruce D Levy; Elliot Israel; Brenda R Phillips; David T Mauger; Suzy A Comhair; Serpil C Erzurum; Mats W Johansson; Nizar N Jarjour; Andrea M Coverstone; Mario Castro; Fernando Holguin; Sally E Wenzel; Prescott G Woodruff; Eugene R Bleecker; John V Fahy Journal: Lancet Respir Med Date: 2016-06-06 Impact factor: 30.700
Authors: Kristen B Corey; Justin H Turner; Naweed I Chowdhury; Rakesh K Chandra; Ping Li; Pingsheng Wu; Katherine N Cahill Journal: J Allergy Clin Immunol Pract Date: 2022-04-08
Authors: Atsushi Kato; Anju T Peters; Whitney W Stevens; Robert P Schleimer; Bruce K Tan; Robert C Kern Journal: Allergy Date: 2021-09-15 Impact factor: 14.710
Authors: Christine Bangert; Sergio Villazala-Merino; Martin Fahrenberger; Thomas Krausgruber; Wolfgang M Bauer; Victoria Stanek; Nicholas James Campion; Tina Bartosik; Tamara Quint; Guenther Regelsberger; Verena Niederberger-Leppin; Christoph Bock; Sven Schneider; Julia Eckl-Dorna Journal: Front Immunol Date: 2022-03-28 Impact factor: 7.561